Braegen-02

Braegen-02
Clinical data
Drug class	TrkB agonist
Identifiers
	IUPAC name 4-[6-oxo-2-(trifluoromethyl)-3H-pyrano[2,3-e]benzimidazol-8-yl]benzonitrile;
CAS Number	2410598-89-7;
PubChem CID	146347459;
ChemSpider	123961613;
Chemical and physical data
Formula	C18H8F3N3O2
Molar mass	355.276 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C#N)C2=CC(=O)C3=C(O2)C4=C(C=C3)NC(=N4)C(F)(F)F;
	InChI InChI=1S/C18H8F3N3O2/c19-18(20,21)17-23-12-6-5-11-13(25)7-14(26-16(11)15(12)24-17)10-3-1-9(8-22)2-4-10/h1-7H,(H,23,24); Key:XWJPZCVKIGMYPF-UHFFFAOYSA-N;

Braegen-02 is a small-molecule drug which acts as a potent and selective agonist of the tropomyosin receptor kinase B (TrkB). It is commonly referred to as CF3CN due to the CF₃ and CN groups in its chemical structure, but this may cause confusion with the unrelated chemical trifluoroacetonitrile which has the chemical formula CF₃CN. As with many TrkB agonists it was derived through modification of the natural product TrkB agonist 7,8-dihydroxyflavone, but it is more potent than earlier derivatives such as R13. It is under development as a potential treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease.^[1]^[2]^[3]^[4]

References